NR4A1 and breast cancer: Monotherapy of solid neoplasms with PI3K inhibitors proved ineffective, however, several compounds have already been approved for the treatment of PIK3CA-mutated hormone-receptor (HR)-positive/HER2-negative breast cancer (BC) in combination with other agents.